Atezolizumab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer, Colorectal Cancer, Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma, Bladder Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (3)
US
  • Alveolar Soft Part Sarcoma (ASPS) for the treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic ASPS.
Product first approved 2016Outside this platform's coverageFDA label
JP
  • Unresectable, advanced or recurrent non-small cell lung cancer (applicant Chugai)
Product first approved 2018roche.com
EU
  • Urothelial carcinoma (first listed indication); later extended to NSCLC and other cancers
Product first approved 2017EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (93)
Bladder Cancer
NCT03799835 · UNICANCER
2019-01-17 – 2028-10 · Bladder Cancer
What this study did
NCT03775265 · National Cancer Institute (NCI)
2019-06-03 – 2027-11-13 · Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
What this study did
NCT02302807 · Hoffmann-La Roche
2015-01-13 – 2018-11-08 · Bladder Cancer
What this study did
Colorectal Cancer
NCT06733038 · Gruppo Oncologico del Nord-Ovest
2024-11-15 – 2029-04-01 · Colorectal Cancer
What this study did
NCT02997228 · National Cancer Institute (NCI)
2018-01-19 – 2027-06-01 · Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7
What this study did
NCT05425940 · Exelixis
2022-09-07 – 2027-01-31 · Colorectal Cancer
What this study did
Hepatocellular Carcinoma
NCT06680258 · Tempest Therapeutics
2025-12 – 2030-07 · Hepatocellular Carcinoma (HCC)
What this study did
NCT07620574 · Exelixis
2026-07-30 – 2030-05-31 · Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET), Hepatocellular Carcinoma (HCC), Differentiated Thyroid Cancer (DTC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Colorectal Cancer, Prostate Cancer
What this study did
NCT07461675 · University of Geneva, Switzerland
2026-03-25 – 2029-12-31 · Hepato Cellular Carcinoma (HCC), Immunotherapy
What this study did
NCT04712643 · Hoffmann-La Roche
2021-03-12 – 2029-02-01 · Hepatocellular Carcinoma
What this study did
NCT05482516 · Georgetown University
2023-03-29 – 2027-12 · Colon Adenocarcinoma, Rectal Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma, Adenocarcinoma of Biliary Tract, Gallbladder Adenocarcinoma
What this study did
NCT04803994 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2021-07-06 – 2027-07 · Hepatocellular Carcinoma
What this study did
NCT04770896 · Hoffmann-La Roche
2021-04-26 – 2026-10-14 · Unresectable Hepatocellular Carcinoma
What this study did
Melanoma
NCT03273153 · Hoffmann-La Roche
2017-12-11 – 2021-02-19 · Advanced BRAFV600 Wild-type Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT07388524 · National Cancer Institute (NCI)
2027-03-02 – 2032-09-30 · Lung Non-Small Cell Carcinoma
What this study did
NCT06632327 · Alliance for Clinical Trials in Oncology
2024-12-11 – 2030-04-30 · Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
What this study did
NCT04214262 · National Cancer Institute (NCI)
2020-08-13 – 2027-06-09 · Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
What this study did
NCT05047250 · Hoffmann-La Roche
2022-06-14 – 2027-01-29 · Non-Small Cell Lung Cancer
What this study did
NCT03977194 · Intergroupe Francophone de Cancerologie Thoracique
2019-07-23 – 2026-12 · Non Small Cell Lung Cancer Metastatic
What this study did
NCT03520686 · ImmunityBio, Inc.
2018-05-18 – 2025-10-13 · Non Small Cell Lung Cancer
What this study did
NCT04513925 · Hoffmann-La Roche
2020-08-24 – 2025-07-31 · Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT03735121 · Hoffmann-La Roche
2018-12-27 – 2024-11-11 · Non-Small Cell Lung Cancer
What this study did
NCT03991403 · Samsung Medical Center
2019-08-27 – 2024-03-11 · Non-small Cell Lung Cancer
What this study did
NCT02813785 · Hoffmann-La Roche
2016-07-01 – 2022-12-27 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT03922997 · Hoffmann-La Roche
2019-07-03 – 2022-08-11 · Non-small Cell Lung Cancer
What this study did
Small Cell Lung Cancer
NCT07947121 · GlaxoSmithKline
2026-12-25 – 2032-03-24 · Lung Neoplasm
What this study did
NCT07625644 · SystImmune Inc.
2026-08-04 – 2031-06 · Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc, SCLC,Extensive Stage, Lung Cancer, Lung Cancer Metastatic, Lung Cancer Stage IV
What this study did
NCT07472517 · Boehringer Ingelheim
2026-04-13 – 2029-07-30 · Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
What this study did
NCT03811002 · National Cancer Institute (NCI)
2019-07-26 – 2029-02-21 · Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
What this study did
Phase 2/3 (12)
Colorectal Cancer
NCT05770102 · Cancer Research UK
2023-10-25 – 2029-10 · Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Colorectal Neoplasms, Endometrial Neoplasms, Melanoma, Solid Tumours
What this study did
NCT05141721 · Seattle Project Corporation
2022-02-12 – 2027-03 · Colorectal Neoplasms
What this study did
Hepatocellular Carcinoma
NCT07285850 · Eastern Hepatobiliary Surgery Hospital
2025-10-20 – 2026-08-30 · HCC - Hepatocellular Carcinoma
What this study did
NCT05665348 · Federation Francophone de Cancerologie Digestive
2023-03-09 – 2025-05-12 · HCC - Hepatocellular Carcinoma, Metastatic Cancer, Metastatic Tumor
What this study did
Non-Small Cell Lung Cancer
NCT03178552 · Hoffmann-La Roche
2017-09-22 – 2027-06-30 · Non-Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT05722886 · Cancer Research UK
2023-03-01 – 2029-10 · Haematological Malignancy, Solid Tumour
What this study did
NCT05058651 · National Cancer Institute (NCI)
2022-06-28 – 2028-10-01 · Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma, Recurrent Extrapulmonary Neuroendocrine Carcinoma, Unresectable Extrapulmonary Neuroendocrine Carcinoma
What this study did
NCT05063552 · National Cancer Institute (NCI)
2023-03-13 – 2027-12-15 · Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Lip and Oral Cavity Carcinoma, Metastatic Nasal Cavity Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Pharyngeal Squamous Cell Carcinoma, Metastatic Sinonasal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Pharyngeal Squamous Cell Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
What this study did
NCT02839707 · National Cancer Institute (NCI)
2017-06-23 – 2027-05-11 · Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube Undifferentiated Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Undifferentiated Carcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Undifferentiated Carcinoma
What this study did
NCT01810913 · National Cancer Institute (NCI)
2013-03-22 – 2027-01-01 · Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7
What this study did
NCT05694013 · Hoffmann-La Roche
2023-02-27 – 2024-06-30 · Cancer
What this study did
Phase 2 (334)
Bladder Cancer
NCT04138628 · Jørgen Bjerggaard Jensen
2020-03-24 – 2030-11-01 · Bladder Cancer, Bladder Cancer, Metastatic
What this study did
NCT04630730 · Swiss Cancer Institute
2022-06-24 – 2030-06 · Bladder Cancer
What this study did
NCT05312671 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2022-06-27 – 2029-10 · Small Cell Neuroendocrine Carcinoma of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder
What this study did
NCT03697850 · UNICANCER
2018-12-14 – 2029-02-15 · Bladder Cancer
What this study did
NCT03237780 · National Cancer Institute (NCI)
2018-07-20 – 2027-06-30 · Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma, Unresectable Urethral Urothelial Carcinoma
What this study did
NCT04186013 · Spanish Oncology Genito-Urinary Group
2019-09-18 – 2027-05 · Bladder Cancer
What this study did
NCT03093922 · Memorial Sloan Kettering Cancer Center
2017-03-22 – 2026-09-22 · Urothelial Carcinoma, Locally Advanced, Unresectable
What this study did
NCT04941287 · National Cancer Institute (NCI)
2021-12-15 – 2026-04-29 · Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Recurrent Distal Bile Duct Adenocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Liver Carcinoma
What this study did
NCT04289779 · Deepak Kilari
2020-05-21 – 2025-12 · Bladder Cancer
What this study did
NCT02844816 · National Cancer Institute (NCI)
2017-03-13 – 2024-06-26 · Recurrent Bladder Urothelial Carcinoma, Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7, Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7, Stage I Bladder Urothelial Carcinoma AJCC v6 and v7
What this study did
NCT03513952 · National Cancer Institute (NCI)
2019-06-05 – 2024-04-01 · Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma
What this study did
NCT03201458 · National Cancer Institute (NCI)
2018-02-08 – 2024-02-19 · Gallbladder Carcinoma, Metastatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Cholangiocarcinoma
What this study did
NCT05564416 · National Cancer Institute (NCI)
2023-10-12 – 2024-01-01 · Bladder Carcinoma, Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Renal Pelvis and Ureter Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage III Bladder Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Urothelial Carcinoma
What this study did
NCT02091141 · Genentech, Inc.
2014-04-14 – 2023-05-24 · Neoplasms, Solid Tumors, Biliary Cancer, Salivary Cancer, Bladder Cancer
What this study did
NCT02451423 · Lawrence Fong
2016-03-29 – 2023-03-31 · Carcinoma, Transitional Cell
What this study did
NCT02108652 · Hoffmann-La Roche
2014-05-31 – 2023-02-28 · Bladder Cancer
What this study did
NCT02951767 · Hoffmann-La Roche
2014-05-31 – 2023-02-28 · Bladder Cancer
What this study did
NCT03628716 · Bavarian Nordic
2018-09-18 – 2021-02-02 · Bladder Cancer
What this study did
NCT03620435 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2018-05-01 – 2020-12-30 · Safety Issues
What this study did
NCT02662309 · Queen Mary University of London
2016-02-01 – 2020-06-11 · Bladder Cancer
What this study did
Colorectal Cancer
NCT05999812 · University of Texas Southwestern Medical Center
2023-12-19 – 2028-10-01 · Colorectal Cancer
What this study did
NCT06784947 · University of Colorado, Denver
2025-03-25 – 2028-05 · Microsatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC), Colorectal Cancer Stage IV
What this study did
NCT07235293 · Kahr Bio Australia Pty Ltd
2026-01-16 – 2027-04-30 · Colorectal Cancer
What this study did
NCT05118724 · AIO-Studien-gGmbH
2021-12-10 – 2027-04 · Colorectal Cancer
What this study did
NCT02992912 · Gustave Roussy, Cancer Campus, Grand Paris
2016-11-15 – 2026-06-29 · Patients With Metastatic Tumours (Colorectal Cancer, Non-small Lung Cancer, Renal Cell Carcinoma or Sarcoma )
What this study did
NCT05733611 · Replimune, Inc.
2023-06-29 – 2025-08-18 · Refractory Metastatic Colorectal Cancer, pMMR, MSS
What this study did
NCT06603818 · National Cancer Institute (NCI)
2025-08-15 – 2025-08-15 · Microsatellite Stable Metastatic Colorectal Cancer, Metastatic Colorectal Cancer, Colorectal Cancer
What this study did
NCT03340558 · Niharika Mettu
2018-05 – 2025-02 · Metastatic Colorectal Cancer
What this study did
NCT05243862 · Treos Bio Limited
2022-06-02 – 2025-01-14 · Colorectal Cancer Metastatic
What this study did
NCT04659382 · Federation Francophone de Cancerologie Digestive
2020-10-07 – 2024-10-31 · Metastatic Colorectal Cancer, pMMR, MSS, Immune Checkpoint Inhibitor, Internal Radiotherapy
What this study did
NCT02873195 · Academic and Community Cancer Research United
2017-07-07 – 2023-12-01 · Metastatic Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
What this study did
NCT03698461 · Asan Medical Center
2019-05-15 – 2023-10-24 · Colorectal Neoplasms, Neoplasm Metastasis, Colonic Neoplasms, Rectal Neoplasms
What this study did
NCT03721653 · Gruppo Oncologico del Nord-Ovest
2018-11-30 – 2023-08-31 · Metastatic Colorectal Cancer
What this study did
NCT05456165 · Gritstone bio, Inc.
2022-05-19 – 2022-09-01 · Colonic Neoplasms, Colorectal Neoplasms
What this study did
NCT02291289 · Hoffmann-La Roche
2015-04-17 – 2021-03-24 · Colorectal Cancer
What this study did
NCT02982694 · Vall d'Hebron Institute of Oncology
2017-11-24 – 2020-11-27 · MSI, ColoRectal Cancer, Chemotherapy, Resistance, APC
What this study did
Hepatocellular Carcinoma
NCT05620771 · Northwestern University
2022-11-30 – 2040-07-01 · Hepatocellular Carcinoma
What this study did
NCT06605664 · Chang Gung Memorial Hospital
2025-05-01 – 2031-09-30 · Hepatocellular Carcinoma (HCC)
What this study did
NCT07018947 · Fundacion Clinic per a la Recerca Biomédica
2026-06-02 – 2031-06 · Resectable Hepatocellular Carcinoma
What this study did
NCT06339424 · Chang Gung Memorial Hospital
2024-03-30 – 2031-03-30 · Hepatocellular Carcinoma
What this study did
NCT04727307 · University Hospital, Montpellier
2021-02-23 – 2031-02 · Hepatocellular Carcinoma
What this study did
NCT07317414 · Peking Union Medical College Hospital
2025-12-24 – 2030-12-05 · Hepatocellular Carcinoma
What this study did
NCT07239245 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2025-11-12 – 2030-11-10 · Resectable Hepatocellular Carcinoma With High Risk of Recurrence
What this study did
NCT06133062 · Chang Gung Memorial Hospital
2023-11-16 – 2030-09-30 · Hepatocellular Carcinoma Non-resectable
What this study did
NCT05528952 · Centre Hospitalier Universitaire de Besancon
2022-09-27 – 2030-02-27 · Hepatocellular Carcinoma
What this study did
NCT06789757 · Inova Health Care Services
2025-02-25 – 2030-01-27 · Hepatocellular Carcinoma
What this study did
NCT06254248 · Assistance Publique - Hôpitaux de Paris
2026-01-22 – 2030-01-01 · Liver Transplant, Hepatocellular Carcinoma Recurrent, Systemic Treatment
What this study did
NCT07774247 · CHA University
2026-09-01 – 2029-09-01 · Hepatocellular Carcinoma (HCC)
What this study did
NCT07010497 · Asan Medical Center
2026-03-16 – 2029-03-31 · Carcinoma, Hepatocellular
What this study did
NCT05733598 · Replimune, Inc.
2024-08-01 – 2028-07-01 · Hepatocellular Carcinoma, Biliary Tract Cancer
What this study did
Phase 1/2 (108)
Bladder Cancer
NCT05000294 · University of Florida
2021-12-07 – 2027-06 · Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer, Neuroendocrine Tumors, Ovarian Cancer, Pancreatic Adenocarcinoma, Soft Tissue Sarcoma, Vulvar Cancer, Prostate Cancer
What this study did
NCT02989584 · Memorial Sloan Kettering Cancer Center
2016-12-20 – 2026-12 · Bladder Cancer, Metastatic Bladder Cancer, Urothelial Carcinoma
What this study did
NCT03869190 · Hoffmann-La Roche
2019-06-01 – 2025-12-22 · Urothelial Carcinoma, Bladder Cancer
What this study did
Colorectal Cancer
NCT05944237 · Cancer Research UK
2023-08-02 – 2028-12-31 · Neoplasms, Prostatic Neoplasms, Castration-Resistant, Stomach Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Colorectal Neoplasms, Pancreatic Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Mesothelioma, Malignant, Uterine Cervical Neoplasms, Kidney Neoplasms, Sarcoma, Pheochromocytomas
What this study did
NCT03555149 · Hoffmann-La Roche
2018-09-27 – 2022-09-26 · Colorectal Cancer
What this study did
Hepatocellular Carcinoma
NCT05468359 · St. Jude Children's Research Hospital
2022-11-07 – 2037-06 · Refractory Solid Tumor, Hepatocellular Carcinoma, Malignant Solid Tumor, Pediatric Cancer, Pediatric Solid Tumor, Fibrolamellar Carcinoma
What this study did
NCT06725121 · University Health Network, Toronto
2024-12 – 2034-06 · Hepatocellular Carcinoma (HCC), Macrovascular Invasion, Liver Transplant Surgery, Downstaging
What this study did
NCT03942328 · Mayo Clinic
2019-09-19 – 2030-08-31 · Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Hepatocellular Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
What this study did
NCT07835737 · West China Hospital
2026-10-01 – 2029-10-01 · Unresectable Hepatocellular Carcinoma
What this study did
NCT05109052 · University of Rochester
2022-09-20 – 2028-12-31 · Hepatocellular Carcinoma, Cancer of Liver
What this study did
NCT06294548 · University of Alabama at Birmingham
2025-07-29 – 2028-08-28 · Hepatocellular Carcinoma
What this study did
NCT05440708 · Tvardi Therapeutics, Incorporated
2023-03-23 – 2027-07-20 · Hepatocellular Carcinoma
What this study did
NCT05908786 · Hoffmann-La Roche
2023-12-05 – 2025-11-13 · Carcinoma, Hepatocellular
What this study did
NCT06006286 · M.D. Anderson Cancer Center
2023-08-08 – 2023-11-10 · Metastatic Hepatocellular Carcinoma
What this study did
Melanoma
NCT05116202 · Hoffmann-La Roche
2022-02-02 – 2024-05-28 · Melanoma
What this study did
NCT03901573 · NeoImmuneTech
2019-12-26 – 2023-08-15 · Melanoma, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
What this study did
NCT04123470 · Lokon Pharma AB
2020-01-28 – 2023-07-30 · Malignant Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT04691817 · Abramson Cancer Center at Penn Medicine
2023-07-25 – 2027-09 · Lung Cancer, Nonsmall Cell
What this study did
NCT04467723 · University of Kansas Medical Center
2022-05-18 – 2027-08 · NSCLC Stage IV, NSCLC, Recurrent
What this study did
NCT05501665 · Vanderbilt-Ingram Cancer Center
2023-05-09 – 2027-02-01 · Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage III Lung Cancer
What this study did
NCT05240131 · Galecto Biotech AB
2022-03-15 – 2025-11-01 · Non-Small Cell Lung Cancer
What this study did
NCT04440735 · Kahr Medical
2020-10-07 – 2025-09 · Advanced Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer
What this study did
NCT03568656 · CellCentric Ltd.
2018-07-23 – 2025-07-06 · Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Advanced Solid Tumors
What this study did
NCT04902040 · M.D. Anderson Cancer Center
2021-04-14 – 2025-02-27 · Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Merkel Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Stage III Bladder Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT03829501 · Kymab Limited
2019-01-28 – 2024-10-03 · Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Esophageal Cancer, Gastric Cancer, Melanoma, Renal Cell Carcinoma, Pancreatic Cancer, Cervical Cancer, Triple Negative Breast Cancer, Advanced Cancer, Metastatic Cancer
What this study did
NCT06090318 · Rain Oncology Inc
2023-05-19 – 2023-05-30 · Advanced Solid Tumor, CDKN2A, NSCLC, Urothelial Carcinoma Bladder, Melanoma, Pancreas Adenocarcinoma, HNSCC, Renal Cell Carcinoma, Mesothelioma, Gastric Cancer
What this study did
NCT04471415 · Dracen Pharmaceuticals, Inc.
2020-08-31 – 2023-03-28 · Advanced Solid Tumor, Non Small Cell Lung Cancer Metastatic
What this study did
NCT03138889 · Nektar Therapeutics
2017-06-09 – 2022-08-24 · Non-Small Cell Lung Cancer
What this study did
NCT04639245 · Fred Hutchinson Cancer Center
2021-07-19 – 2022-08-16 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Triple-Negative Breast Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
NCT03023423 · Janssen Research & Development, LLC
2016-12-23 – 2019-09-26 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT02630186 · Clovis Oncology, Inc.
2016-02-24 – 2017-09-05 · Non-small Cell Lung Cancer
What this study did
Small Cell Lung Cancer
NCT07227597 · Merck Sharp & Dohme LLC
2026-01-29 – 2030-12-30 · Small Cell Lung Cancer Extensive Stage
What this study did
NCT07707895 · Boehringer Ingelheim
2026-11-03 – 2030-04-26 · Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology, Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology
What this study did
NCT06287775 · National Cancer Institute (NCI)
2025-04-08 – 2029-07-25 · Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
NCT07407933 · MediLink Therapeutics (Suzhou) Co., Ltd.
2026-03-31 – 2029-02 · Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma
What this study did
NCT05652686 · Phanes Therapeutics
2023-09-05 – 2028-08 · Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), Neuroendocrine Carcinomas (NEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
What this study did
NCT05703971 · Genprex, Inc.
2024-05-09 – 2028-06 · Small Cell Lung Cancer Extensive Stage
What this study did
NCT05142696 · Novartis Pharmaceuticals
2022-07-13 – 2028-03-07 · Extensive Stage Small Cell Lung Cancer
What this study did
NCT04471727 · Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
2020-12-14 – 2028-01-28 · Small-Cell Lung Cancer, Neuroendocrine Carcinoma
What this study did
NCT06939036 · Ariceum Therapeutics GmbH
2025-07-01 – 2025-12-31 · Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma
What this study did
NCT04487756 · Instituto Oncológico Dr Rosell
2021-03-17 – 2025-09-08 · Extensive-stage Small Cell Lung Cancer
What this study did
NCT04253145 · Fundacion Oncosur
2019-12-13 – 2025-05 · Carcinoma, Small Cell Lung
What this study did
NCT05253053 · TransThera Sciences (Nanjing), Inc.
2022-04-13 – 2024-08-31 · Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Small-cell Lung Cancer, Bladder Cancer, Prostate Cancer, Thyroid Cancer, Gastric Cancer, Gallbladder Cancer
What this study did
NCT04101357 · BioNTech SE
2020-06-19 – 2024-05-23 · Solid Tumor, Extensive-stage Small Cell Lung Cancer
What this study did
NCT05191797 · University of Washington
2022-04-11 – 2024-04-05 · Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma
What this study did
NCT02748889 · Giuseppe Giaccone
2016-03 – 2017-05-09 · Small Cell Lung Cancer ( SCLC )
What this study did
Other / comorbidity
NCT03424005 · Hoffmann-La Roche
2018-03-30 – 2030-09-30 · Metastatic Breast Cancer
What this study did
Phase 1 (150)
Bladder Cancer
NCT04134000 · Fundacion Oncosur
2020-02-03 – 2024-09 · Invasive Bladder Cancer
What this study did
NCT03650348 · Pieris Pharmaceuticals, Inc.
2018-08-21 – 2022-08-11 · HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Bladder Cancer, HER2-positive Solid Tumor
What this study did
NCT03359239 · Matthew Galsky
2019-05-08 – 2021-10-12 · Urothelial/Bladder Cancer, Nos
What this study did
Colorectal Cancer
NCT04929223 · Hoffmann-La Roche
2021-10-22 – 2030-08-31 · Metastatic Colorectal Cancer
What this study did
NCT06012734 · The Netherlands Cancer Institute
2024-06-18 – 2028-07 · Metastatic Microsatellite-stable Colorectal Cancer
What this study did
NCT03845166 · Exelixis
2019-03-20 – 2027-05-31 · Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer
What this study did
NCT04713891 · Keythera Pharmaceuticals (Australia) Pty Ltd
2021-03-09 – 2023-04-27 · Advanced Solid Tumor, Colorectal Cancer, Lung Cancer, Squamous Cell Carcinoma of the Esophagus, Gastric Cancer, Bladder Cancer
What this study did
NCT03256344 · Amgen
2018-03-19 – 2021-12-03 · Metastatic Triple Negative Breast Cancer, Metastatic Colorectal Cancer
What this study did
NCT02876224 · Hoffmann-La Roche
2016-09-30 – 2019-06-25 · Colorectal Cancer
What this study did
Hepatocellular Carcinoma
NCT05096715 · Massachusetts General Hospital
2022-08-23 – 2032-01-31 · Unresectable Hepatocellular Carcinoma
What this study did
NCT05546879 · University Hospital, Grenoble
2023-03-15 – 2029-03-19 · Hepatocellular Carcinoma
What this study did
NCT06478693 · Myeloid Therapeutics
2024-07-01 – 2028-05-31 · Hepatocellular Carcinoma
What this study did
NCT05097911 · National University Hospital, Singapore
2021-08-02 – 2027-04 · Advanced Hepatocellular Carcinoma
What this study did
NCT05488522 · Abramson Cancer Center at Penn Medicine
2022-09-01 – 2026-12-31 · Hepatocellular Carcinoma
What this study did
NCT04857684 · Massachusetts General Hospital
2021-06-18 – 2026-12-31 · Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma
What this study did
NCT05092373 · M.D. Anderson Cancer Center
2022-04-29 – 2026-09-01 · Advanced Breast Carcinoma, Advanced Endometrial Carcinoma, Advanced Fallopian Tube Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Malignant Abdominal Neoplasm, Advanced Malignant Female Reproductive System Neoplasm, Advanced Malignant Thoracic Neoplasm, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Renal Cell Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Malignant Abdominal Neoplasm, Malignant Solid Neoplasm, Metastatic Breast Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Malignant Abdominal Neoplasm, Metastatic Malignant Female Reproductive System Neoplasm, Metastatic Malignant Thoracic Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Metastatic Renal Cell Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage III Uterine Corpus Cancer AJCC v8, Stage IIIA Fallopian Tube Cancer AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Primary Peritoneal Cancer AJCC v8, Stage IIIA Uterine Corpus Cancer AJCC v8, Stage IIIA1 Fallopian Tube Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Fallopian Tube Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Fallopian Tube Cancer AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Primary Peritoneal Cancer AJCC v8, Stage IIIB Uterine Corpus Cancer AJCC v8, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IIIC Uterine Corpus Cancer AJCC v8, Stage IIIC1 Uterine Corpus Cancer AJCC v8, Stage IIIC2 Uterine Corpus Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8
What this study did
NCT05022927 · Chugai Pharmaceutical
2021-06-01 – 2025-12-31 · Hepatocellular Carcinoma (HCC)
What this study did
NCT05093608 · H. Lee Moffitt Cancer Center and Research Institute
2021-11-03 – 2022-10-12 · Hepatocellular Carcinoma
What this study did
Melanoma
NCT04020809 · The Methodist Hospital Research Institute
2020-09-25 – 2026-10-01 · Cutaneous Melanoma
What this study did
NCT04109456 · InxMed (Shanghai) Co., Ltd.
2020-03-16 – 2024-12-20 · Metastatic Melanoma
What this study did
NCT04096638 · invoX Pharma Limited
2019-09-23 – 2024-07-16 · Melanoma, Head and Neck Squamous Cell Carcinoma, Solid Tumor
What this study did
Non-Small Cell Lung Cancer
NCT06332755 · LG Chem
2024-06-05 – 2028-12 · Non-small Cell Lung Cancer(NSCLC), Head and Neck Squamous Cell Carcinoma(HNSCC), Renal Cell Carcinoma(RCC), Urothelial Carcinoma, Malignant Melanoma
What this study did
NCT05334329 · University of California, Irvine
2022-07-20 – 2028-11-30 · Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT05581004 · Genentech, Inc.
2022-10-20 – 2028-07-31 · Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma, TNBC, Esophageal Cancer, Gastric Cancer, Cervical Cancer, Colorectal Cancer, Urothelial Carcinoma, Clear Cell RCC, HCC
What this study did
NCT06066138 · National Cancer Institute (NCI)
2025-11-04 – 2028-01-31 · Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Locally Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Locally Advanced Small Cell Lung Cancer, Metastatic Small Cell Lung Cancer, Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Locally Advanced Melanoma, Metastatic Melanoma
What this study did
NCT04449874 · Genentech, Inc.
2020-07-29 – 2027-12-31 · Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors
What this study did
NCT06444815 · KaliVir Immunotherapeutics
2024-09-16 – 2027-12-31 · Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Kidney Cancer, Renal Cell Carcinoma, Melanoma Stage IV, Merkel Cell Carcinoma of Skin, Mesothelioma, Non-small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Urothelial Carcinoma Bladder, Squamous Cell Carcinoma
What this study did
NCT06616623 · Dwight Owen
2024-12-31 – 2027-12-01 · Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
NCT03170960 · Exelixis
2017-09-05 – 2027-09-30 · Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Head and Neck Cancer, Differentiated Thyroid Cancer, Lower Esophageal Cancer
What this study did
NCT04919369 · Dwight Owen
2021-10-18 – 2026-07-03 · Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT03289962 · Genentech, Inc.
2017-12-21 – 2025-07-01 · Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Renal Cancer, Head and Neck Cancer, Other Solid Cancers
What this study did
NCT04911166 · The Methodist Hospital Research Institute
2021-10-14 – 2025-04-01 · Non-small Cell Lung Cancer
What this study did
NCT05259319 · Centre Georges Francois Leclerc
2022-12-05 – 2024-12-05 · Metastatic Non Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Renal Cell Carcinoma, Metastatic Head and Neck Cancer
What this study did
NCT04432207 · Imugene Limited
2020-11-30 – 2024-11-07 · Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, Squamous Non-small-cell Lung Cancer, Large Cell Carcinoma Lung, Adenocarcinoma Lung
What this study did
NCT04081688 · Rutgers, The State University of New Jersey
2019-09-11 – 2024-04-30 · Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
NCT02599454 · Megan Daly, MD
2018-04-26 – 2024-02-20 · Stage I Non-Small Cell Lung Cancer
What this study did
NCT05395052 · Fate Therapeutics
2022-05-31 – 2023-08-11 · Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer
What this study did
NCT03841110 · Fate Therapeutics
2019-02-15 – 2022-11-15 · Advanced Solid Tumors, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR Positive Solid Tumor, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Small Cell Lung Cancer, Renal Cell Carcinoma, Pancreas Cancer, Melanoma, NSCLC, Urothelial Carcinoma, Cervical Cancer, Microsatellite Instability, Merkel Cell Carcinoma
What this study did
NCT03498222 · Queen Mary University of London
2018-06-01 – 2021-12-31 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT02400814 · Megan Daly, MD
2015-12-03 – 2021-09-29 · Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
What this study did
NCT02013219 · Hoffmann-La Roche
2014-04-03 – 2020-02-05 · Non-Small Cell Lung Cancer
What this study did
NCT03455556 · Mayo Clinic
2018-08-10 – 2020-01-07 · Mesothelin Positive, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
What this study did
NCT03438318 · Regeneron Pharmaceuticals
2018-03-15 – 2019-12-11 · Non Small Cell Lung Cancer
What this study did
NCT02463994 · University of Michigan Rogel Cancer Center
2015-10 – 2018-11-07 · Non-small Cell Lung Cancer
What this study did
NCT02919449 · Vyriad, Inc.
2017-08-03 – 2018-01-19 · Recurrent Non-Small Cell Lung Cancer
What this study did
NCT02298153 · Incyte Corporation
2015-01-27 – 2017-11-08 · NSCLC (Non-small Cell Lung Carcinoma), UC (Urothelial Cancer)
What this study did
Phase 4 (7)
Hepatocellular Carcinoma
NCT05185505 · The Methodist Hospital Research Institute
2023-01-30 – 2028-10-31 · Hepatocellular Carcinoma, Hepatocellular Cancer
What this study did
NCT07059494 · Icahn School of Medicine at Mount Sinai
2026-03-26 – 2028-08-01 · Hepatocellular Carcinoma
What this study did
NCT05717400 · M.D. Anderson Cancer Center
2023-03-17 – 2024-08-29 · Liver Cancer
What this study did
Non-Small Cell Lung Cancer
NCT05689671 · Nikolaj Frost MD
2023-12-06 – 2026-10 · Non-Small Cell Lung Cancer Metastatic
What this study did
Other / comorbidity
NCT06031233 · Isala
2023-09-01 – 2028-12 · Oncology, Infusion Reaction
What this study did
NCT04059887 · Chonnam National University Hospital
2019-12-18 – 2022-06-30 · Lung Neoplasm Malignant
What this study did
Early phase / not applicable (13)
Bladder Cancer
NCT03577132 · Seoul National University Hospital
2018-08-01 – 2022-05-31 · Urothelial Carcinoma
What this study did
Hepatocellular Carcinoma
NCT07281664 · Third Affiliated Hospital, Sun Yat-Sen University
2026-01-01 – 2029-12-31 · Hepatocellular Carcinoma, Transarterial Chemoembolization
What this study did
NCT07543510 · Third Affiliated Hospital, Sun Yat-Sen University
2026-05-01 – 2029-08-31 · Hepatocellular Carcinoma, Atezolizumab Plus Bevacizumab, Transarterial Chemoembolization
What this study did
NCT06595108 · Yonsei University
2024-05-28 – 2028-03-27 · Advanced Hepatocellular Carcinoma, Chemotherapy, Stereotactic Body Radiotherapy
What this study did
NCT04180072 · National Health Research Institutes, Taiwan
2020-03-12 – 2026-12-31 · Carcinoma, Hepatocellular
What this study did
NCT06961526 · Tanta University
2025-02-15 – 2026-07 · Esophageal and/or Gastric Varices, Hepatocellular Carcinoma (HCC)
What this study did
NCT06609863 · Sun Yat-sen University
2024-10-01 – 2026-06-30 · Advanced Hepatocellular Carcinoma, Atezolizumab, Bevacizumab, Chemotherapy
What this study did
NCT05705791 · Gustave Roussy, Cancer Campus, Grand Paris
2023-02-07 – 2025-12-24 · Hepatocellular Carcinoma
What this study did
NCT07272265 · Sun Yat-sen University
2020-10-28 – 2025-11-10 · Hepatocellular Carcinoma (HCC)
What this study did
Other / comorbidity
NCT02453984 · University Medical Center Groningen
2016-02-24 – 2024-06 · Locally Advanced or Metastatic Solid Tumors Irrespective of PD-L1 Expression
What this study did
NCT04801966 · Peter MacCallum Cancer Centre, Australia
2021-09-23 – 2022-12-30 · Cancer
What this study did
NCT03850028 · University Medical Center Groningen
2019-05-22 – 2022-05-01 · Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
What this study did
Used as active comparator (17)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (8)
Hepatocellular Carcinoma
NCT06921785 · AstraZeneca
2025-05-06 – 2030-03-15 · Hepatocellular Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT07195695 · Boehringer Ingelheim
2026-01-16 – 2036-09-02 · Non-small Cell Lung Cancer
What this study did
NCT06908993 · Intergroupe Francophone de Cancerologie Thoracique
2025-12-09 – 2028-07-15 · Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation
What this study did
Small Cell Lung Cancer
NCT06712355 · BioNTech SE
2025-02-03 – 2029-07 · Extensive-stage Small-cell Lung Cancer
What this study did
NCT05224141 · Merck Sharp & Dohme LLC
2022-03-24 – 2027-06-07 · Small Cell Lung Carcinoma
What this study did
Other / comorbidity
NCT03452137 · Hoffmann-La Roche
2018-04-03 – 2024-03-06 · Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
What this study did
Phase 2/3 (2)
Phase 2 (4)
Small Cell Lung Cancer
NCT05468489 · Shanghai Henlius Biotech
2022-11-18 – 2027-12-31 · Extensive Stage Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT03756298 · National Cancer Center, Korea
2019-01-15 – 2027-12-31 · Triple Negative Breast Cancer
What this study did
NCT05180006 · Gustave Roussy, Cancer Campus, Grand Paris
2022-02-24 – 2024-12-17 · Breast Cancer
What this study did
Phase 1/2 (3)
Non-Small Cell Lung Cancer
NCT03337698 · Hoffmann-La Roche
2017-12-27 – 2025-11-25 · Carcinoma, Non-Small-Cell Lung
What this study did
Other / comorbidity
NCT06584071 · Biotheus Inc.
2024-12 – 2027-12 · HCC, Liver Cancer
What this study did
NCT06157827 · Nanjing Leads Biolabs Co.,Ltd
2023-12-08 – 2027-03-28 · Advanced Neuroendocrine Carcinoma
What this study did
Appears in other studies (31)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (9)
Hepatocellular Carcinoma
NCT07166406 · NRG Oncology
2026-02-26 – 2034-03-10 · Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
What this study did
NCT05904886 · Hoffmann-La Roche
2023-09-14 – 2026-09-01 · Hepatocellular Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT05317858 · InSightec
2022-08-12 – 2031-12-01 · Brain Tumor, Non Small Cell Lung Cancer
What this study did
Small Cell Lung Cancer
NCT06719336 · Anhui Shi, MD
2024-12-16 – 2028-12-16 · Extensive-stage Small Cell Lung Cancer
What this study did
NCT04665856 · Hoffmann-La Roche
2020-12-21 – 2025-11-17 · Small Cell Lung Carcinoma
What this study did
NCT04256421 · Hoffmann-La Roche
2020-02-04 – 2025-07-31 · Small Cell Lung Cancer
What this study did
Phase 2/3 (2)
Hepatocellular Carcinoma
NCT07293468 · Tuen Mun Hospital
2024-04-01 – 2034-12-31 · Hepatocellular Carcinoma (HCC)
What this study did
Small Cell Lung Cancer
NCT04402788 · National Cancer Institute (NCI)
2021-01-07 – 2027-04-30 · Extensive Stage Lung Small Cell Carcinoma
What this study did
Phase 2 (15)
Bladder Cancer
NCT03693014 · Memorial Sloan Kettering Cancer Center
2018-10-01 – 2027-10 · Metastatic Cancer, Melanoma Cancer, Lung Cancer, Bladder Cancer, Renal Cancer, Head/Neck Cancers
What this study did
Hepatocellular Carcinoma
NCT05690048 · Michael Dill
2025-07-16 – 2028-03 · Immunotherapy, HCC - Hepatocellular Carcinoma
What this study did
NCT07157969 · Peking Union Medical College Hospital
2025-02-19 – 2027-06-30 · HCC - Hepatocellular Carcinoma
What this study did
Melanoma
NCT05060003 · Washington University School of Medicine
2022-11-08 – 2023-11-27 · Stage II Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT06463665 · Genelux Corporation
2024-09-26 – 2029-07 · Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
What this study did
NCT03563716 · Genentech, Inc.
2018-08-10 – 2025-11-14 · Non-small Cell Lung Cancer
What this study did
NCT03511391 · University Hospital, Ghent
2018-03-09 – 2024-01-23 · Urothelial Carcinoma, Melanoma, Renal Cell Carcinoma, Non-small Cell Lung Cancer, Head and Neck Cancer
What this study did
Small Cell Lung Cancer
NCT07172412 · Tianjin Medical University Cancer Institute and Hospital
2025-11 – 2028-12 · Extensive Stage Lung Small Cell Cancer
What this study did
NCT04334941 · National Cancer Institute (NCI)
2020-07-20 – 2027-01-21 · Extensive Stage Lung Small Cell Carcinoma
What this study did
Other / comorbidity
NCT04677504 · Hoffmann-La Roche
2021-02-23 – 2023-08-25 · Biliary Tract Cancer
What this study did
NCT03395899 · Queen Mary University of London
2017-12-21 – 2023-08-18 · Breast Cancer, Estrogen Receptor-positive Breast Cancer
What this study did
NCT03979066 · Gulam Manji
2019-11-01 – 2019-11-03 · Pancreatic Ductal Adenocarcinoma
What this study did
NCT02609984 · Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
2015-04-29 – 2019-02-06 · Sarcoma, Myxoid/Round Cell Liposarcoma, Synovial Sarcoma, Metastatic Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Locally Advanced Sarcoma, Liposarcoma
What this study did
Phase 1/2 (2)
Small Cell Lung Cancer
NCT03830918 · Jonsson Comprehensive Cancer Center
2019-03-06 – 2027-01-03 · Advanced Malignant Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
Other / comorbidity
NCT03721679 · Oncovir, Inc.
2018-09-25 – 2021-01-26 · Solid Cancer
What this study did
Phase 1 (2)
Non-Small Cell Lung Cancer
NCT06097962 · Base Therapeutics (Shanghai) Co., Ltd.
2023-07-01 – 2028-07-01 · NSCLC
What this study did
Other / comorbidity
NCT06098898 · Base Therapeutics (Shanghai) Co., Ltd.
2023-11-01 – 2024-11-01 · Gastric Cancer
What this study did
Early phase / not applicable (1)
Hepatocellular Carcinoma
NCT05984511 · Third Affiliated Hospital, Sun Yat-Sen University
2023-08-30 – 2029-08-01 · Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion, Tumor Thrombus
What this study did

Competitive landscape

This mechanism is crowded: 12 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Non-Small Cell Lung Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Atezolizumab: this drugApprovedMonoclonal antibodyPD-L1Partial signal
NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed
NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1)
Adagrasib (Krazati)ApprovedSmall moleculeKRAS G12CPartial signalFeatured results are non-efficacy only in this race
Afatinib (Gilotrif)ApprovedSmall moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7)
NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1)
Alectinib (Alecensa)ApprovedSmall moleculeALKPartial signal
NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019).
NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabApprovedMultispecific antibodyEGFR x c-METPartial signal
NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results.
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
Avelumab
Approved(overall)
Monoclonal antibodyPD-L1
not yet graded(overall)
No reviewed efficacy summary in this indication
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006).
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
BinimetinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
BrigatinibApprovedSmall moleculeALKPartial signal
NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed
NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01)
CapmatinibApprovedSmall moleculeMETWeak signal
NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months
NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1).
CemiplimabApprovedMonoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
CeritinibApprovedSmall moleculeALKPartial signal
NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1)
NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8)
CrizotinibApprovedSmall moleculeALK, ROS1, MET/HGFR, and RONPartial signal
NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7)
NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Weak signal
NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%).
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Dacomitinib PF-00299804
ApprovedUS marketing discontinued
Small moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11)
NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025).
NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1Reliable signal
NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8)
NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed
EncorafenibApprovedSmall moleculeBRAF V600EWeak signal
NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8)
Ensartinib (Ensacove)ApprovedSmall moleculeALKPartial signal
NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001.
EntrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signal
NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results).
GefitinibApprovedSmall moleculeEGFRPartial signal
NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Partial signal
NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)not yet gradedNo reviewed efficacy summary in this indication
LazertinibApprovedSmall moleculeEGFRPartial signal
NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46)
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
LorlatinibApprovedSmall moleculeALK / ROS1Partial signalNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5)
NecitumumabApprovedMonoclonal antibodyEpidermal growth factor receptor (EGFR)Partial signal
NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1)
NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68)
NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Osimertinib (Tagrisso)ApprovedSmall moleculeEGFRPartial signal
NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2)
NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only in this race
Pemetrexed (Alimta)ApprovedSmall moleculeThymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTPartial signal
NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12)
NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83)
Porfimer SodiumApprovedSmall moleculePhotoactivated radicalsWeak signalFeatured results are safety and non-efficacy only in this race
PralsetinibApprovedSmall moleculeRETPartial signal
NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5)
NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106).
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed
NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL).
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETPartial signal
NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026)
NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002
Sevabertinib (Hyrnuo)ApprovedSmall moleculeEGFR/HER2Weak signalNo reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12CPartial signal
NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68)
NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more.
Sunvozertinib (Zegfrovy)ApprovedSmall moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
TaletrectinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1Partial signalNo reviewed efficacy summary in this indication
Telisotuzumab VedotinApprovedAntibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Tepotinib (Tepmetko)ApprovedSmall moleculeMETWeak signal
NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months
TrametinibApprovedSmall moleculeMEK1/2Partial signal
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Weak signal
NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70)
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signal
NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed
NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ZidesamtinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
Zongertinib (Hernexeos)ApprovedSmall moleculeHER2 Mutant-selectivenot yet gradedNo reviewed efficacy summary in this indication
7MW3711Phase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
Abp 234Phase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
AdebrelimabPhase 3Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Aglatimagene BesadenovecPhase 3Gene therapy / editingHerpes simplex virus thymidine kinase (HSV-tk) gene productnot yet gradedNo reviewed efficacy summary in this indication
ApatinibPhase 3Small moleculeVEGFR2Partial signal
NCT01270386: Primary (PFS): median 4.7 vs 1.9 months, apatinib vs placebo, significantly improved; ORR 12.2% vs 0%; DCR 69% vs 24%.
BecotatugPhase 3Monoclonal antibodyEGFRPartial signal
NCT06380348: Primary endpoint, IRC-assessed progression-free survival vs platinum-pemetrexed: met at a prespecified interim analysis (2026-09-24).
CabozantinibPhase 3Small moleculeMET / VEGFR / AXL / RET (multi-kinase)Partial signal
NCT04471428: Overall Survival (OS) (Up to approximately 24 months): Atezolizumab + Cabozantinib 10.7 months (95% CI 8.8 to 12.3) vs Docetaxel Monotherapy 10.5 months (95% CI 8.6 to 13) missed
CadonilimabPhase 3Multispecific antibodyPD-1×CTLA-4Weak signalNo reviewed efficacy summary in this indication
CamrelizumabPhase 3Monoclonal antibodyPD-1Partial signal
NCT03134872: Primary 1, BICR-assessed PFS in all treated randomized patients (interim analysis): median 11.3 vs 8.3 months, camrelizumab plus carboplatin and pemetrexed vs carboplatin and pemetrexed; HR 0.60 (95% CI 0.45 to 0.79); one-sided p=0.0001, met. Primary 2, BICR-assessed PFS in PD-L1-positive patients: no confirmatory test reported.
EnvafolimabPhase 3Monoclonal antibodyPD-L1Weak signal
NCT05068427: Primary endpoint ORR 6.7% (2/30); DCR 50% (15/30); median PFS 3.5 months
Fetrastobart VedotinPhase 3Antibody–drug conjugatePD-L1not yet gradedNo reviewed efficacy summary in this indication
HLX04 (Hanbeitai)Phase 3Monoclonal antibodyVEGF-APartial signal
NCT03952403: ASTRUM-002 met the primary endpoint of progression-free survival with the combination of serplulimab plus HLX04 (bevacizumab biosimilar) and chemotherapy at interim analysis. A total of 636 patients were randomized 1:1:1 to serplulimab plus HLX04 and chemotherapy (group A), serplulimab plus HLX04 placebo and chemotherapy (group B), or double placebo plus chemotherapy (group C). Serplulimab plus chemotherapy significantly prolonged OS and maintained the PFS benefit compared to chemotherapy; however, the addition of the bevacizumab biosimilar HLX04 did not yield further improvement for first-line treatment of nonsquamous NSCLC.
IBI305Phase 3Monoclonal antibodyVEGF-AReliable signal
NCT02954172: Objective response rate at 18 weeks: 44.3% IBI305 (n=221) vs 46.4% bevacizumab (n=220); odds ratio 0.90 (90% CI 0.756–1.077), prespecified equivalence margin 0.75–1.33.
IBI363Phase 3Multispecific antibodyPD-1 x IL-2Rα (IL2RA)not yet gradedNo reviewed efficacy summary in this indication
INCA33890
Phase 3(overall)
Multispecific antibodyTGF-βR2 and PD-1 (conditional bispecific)not yet gradedNo reviewed efficacy summary in this indication
Intismeran AutogenePhase 3VaccinePatient-specific tumor neoantigens (personalized, up to 34 per patient)not yet gradedNo reviewed efficacy summary in this indication
LY01008Phase 3Monoclonal antibodyVEGF-AReliable signal
NCT03533127: LY01008 vs Avastin (bevacizumab) + paclitaxel/carboplatin, first-line non-squamous NSCLC: ORR 48.5% vs 53.0%; stratified ORR ratio 0.91 (90% CI 0.80-1.04), within prespecified equivalence margin 0.75-1.33 -> equivalence/non-inferiority demonstrated.
Nogapendekin Alfa Inbakicept (Anktiva)Phase 3Protein / enzyme therapeuticIL-15 superagonistnot yet gradedNo reviewed efficacy summary in this indication
Obrixtamig
Phase 3(overall)
Multispecific antibodyDLL3 (Delta-like ligand 3) x CD3not yet gradedNo reviewed efficacy summary in this indication
PenpulimabPhase 3Monoclonal antibodyPD-1Reliable signal
NCT03866993: Primary 1, IRRC-assessed PFS in the ITT population (final analysis): median 7.6 months (95% CI 6.8 to 9.6) penpulimab + chemotherapy vs 4.2 months (95% CI 4.2 to 4.3) placebo + chemotherapy; HR 0.43 (95% CI 0.33 to 0.56); p<0.0001, met. Primary 2, IRRC-assessed PFS in the PD-L1-positive subgroup: median 8.1 vs 4.2 months; HR 0.37 (95% CI 0.27 to 0.52); p<0.0001, met.
PF-08634404Phase 3Multispecific antibodyPD-1 + VEGFnot yet gradedNo reviewed efficacy summary in this indication
PumitamigPhase 3Multispecific antibodyPD-L1 and VEGF-Anot yet gradedNo reviewed efficacy summary in this indication
RelatlimabPhase 3Monoclonal antibodyLAG-3Partial signal
NCT04623775: Part 2 objective response rate by BICR (RECIST 1.1): nivolumab + relatlimab + chemotherapy 50.6% (90% CI 43.8 to 57.4, n=158) vs nivolumab + chemotherapy 43.0% (90% CI 36.2 to 50.1, n=151); odds ratio 1.39 (90% CI 0.94 to 2.05). The Part 1 co-primary (TRAEs leading to discontinuation within 12 weeks) compares two relatlimab regimens: 5.6% vs 12.1% (CT.gov posted results). missed
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
Risvutatug RezetecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
S-1Phase 3Small moleculeThymidylate synthase (via 5-FU, released from tegafur) and dihydropyrimidine dehydrogenase (inhibited by gimeracil)not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05870319: OptiTROP-Lung04 (NCT05870319), primary endpoint median PFS: sacituzumab tirumotecan 8.3 months vs chemotherapy 4.3 months; HR 0.49; p<0.0001
SerplulimabPhase 3Monoclonal antibodyPD-1Weak signal
NCT04033354: At the final analysis, serplulimab plus chemotherapy significantly improved median OS compared to placebo plus chemotherapy (HR 0.73, 95% CI 0.58-0.93; p=0.010); at the second interim analysis, the PFS benefit was maintained in the serplulimab-chemotherapy group (HR 0.53, 95% CI 0.42-0.67).
NCT03952403: Final analysis in nonsquamous NSCLC: median overall survival reached 26.8 months for Hetronifly (serplulimab) plus chemotherapy compared with 20.3 months for chemotherapy alone, a 34% reduction in the risk of death (HR=0.66, 95% CI: 0.52-0.83, P<0.001); median PFS was 11.0 months in Group B versus 5.7 months in the chemotherapy-only arm. No statistical difference was observed for Group A compared to Group B (HR=1.12, p=0.3628).
Sugemalimab (Cejemly)Phase 3Monoclonal antibodyPD-L1Reliable signal
NCT03728556: Progression-free survival (BICR-assessed), GEMSTONE-301: median PFS 10.5 months (sugemalimab) vs 6.2 months (placebo); HR 0.65, 95% CI 0.50-0.84
NCT03789604: Sugemalimab plus chemotherapy improved investigator-assessed PFS at interim analysis: median 7.8 vs 4.9 months, stratified HR 0.50.
Telisotuzumab AdizutecanPhase 3Antibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
TislelizumabPhase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
HLX43Phase 2/3Antibody–drug conjugatePD-L1not yet gradedNo reviewed efficacy summary in this indication
LNS8801
Phase 2/3(overall)
Small moleculeGPER (G protein-coupled estrogen receptor)not yet gradedNo reviewed efficacy summary in this indication
ResiquimodPhase 2/3Small moleculeToll-like receptor 7 and 8 (TLR7/8)not yet gradedNo reviewed efficacy summary in this indication
AL8326Phase 2Small moleculeAurora B / FGFR / VEGFR (multi-kinase)not yet gradedNo reviewed efficacy summary in this indication
BotensilimabPhase 2Monoclonal antibodyCTLA-4not yet gradedNo reviewed efficacy summary in this indication
ChidamidePhase 2Small moleculeHDACWeak signal
NCT05068427: Objective response rate: 6.7% (2/30); disease control rate 50%; median PFS 3.5 months (95% CI 1.9-5.5). Trial stopped early for futility against an expected ORR of 24%. missed
Ifinatamab DeruxtecanPhase 2Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
JS207Phase 2Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
TagitanlimabPhase 2Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
TucatinibPhase 2Small moleculeHER2not yet gradedNo reviewed efficacy summary in this indication
VisugromabPhase 2Monoclonal antibodyGDF-15not yet gradedNo reviewed efficacy summary in this indication
Vusolimogene Oderparepvec (Tudriqev)Phase 2Oncolytic virusNo discrete molecular targetnot yet gradedNo reviewed efficacy summary in this indication
ZanzalintinibPhase 2Small moleculeVEGFR2; MET; AXL; MER; TYRO3not yet gradedNo reviewed efficacy summary in this indication
A2B530Phase 1/2Cell therapyCEA / carcinoembryonic antigen (activator) / HLA-A*02 (blocker)not yet gradedNo reviewed efficacy summary in this indication
BGB-B2033Phase 1/2Multispecific antibodyGPC3 (glypican-3) x 4-1BB (CD137)not yet gradedNo reviewed efficacy summary in this indication
CetrelimabPhase 1/2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
DSP107Phase 1/2Protein / enzyme therapeuticSIRP-alpha/4-1BBL fusion proteinnot yet gradedNo reviewed efficacy summary in this indication
Enfortumab VedotinPhase 1/2Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
EvalstotugPhase 1/2Biologic (subtype unspecified)CTLA-4not yet gradedNo reviewed efficacy summary in this indication
N-DihydrogalactochitosanPhase 1/2PolysaccharideSTING and inflammasome pathwaysnot yet gradedNo reviewed efficacy summary in this indication
NilvanstomigPhase 1/2Biologic (subtype unspecified)PD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
OBX-115Phase 1/2Cell therapyIL-15 receptor signalingnot yet gradedNo reviewed efficacy summary in this indication
Quaratusugene Ozeplasmid (Reqorsa)Phase 1/2Gene therapy / editingTUSC2 (tumor suppressor gene replacement)not yet gradedNo reviewed efficacy summary in this indication
Tambotatug PelitecanPhase 1/2Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
TuvutromstatPhase 1/2Small moleculeMAT2AWeak signalNo reviewed efficacy summary in this indication
VSV-IFNβ-NISPhase 1/2Oncolytic virusOncolytic VSV expressing interferon-beta and NISnot yet gradedNo reviewed efficacy summary in this indication
177Lu-RAD204Phase 1RadiopharmaceuticalPD-L1not yet gradedNo reviewed efficacy summary in this indication
ABBV-324Phase 1Antibody–drug conjugateGlypican-3 (GPC3) / Topoisomerase Inot yet gradedNo reviewed efficacy summary in this indication
BBO-10203Phase 1Small moleculeRAS:PI3Kα protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
BPI-371153Phase 1Small moleculePD-L1not yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
HS-IT101Phase 1Cell therapyAutologous tumor neoantigens (polyclonal, patient-specific)not yet gradedNo reviewed efficacy summary in this indication
IBC-Ab002
Phase 1(overall)
Monoclonal antibodyPD-L1
Partial signal(overall)
No reviewed efficacy summary in this indication
KRAS-Specific Autologous TCR-T CellPhase 1Cell therapyKRAS G12V presented on HLA-A*11:01not yet gradedNo reviewed efficacy summary in this indication
LY4066434
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
PalupiprantPhase 1Small moleculeEP4Weak signalNo reviewed efficacy summary in this indication
PF-07934040
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
Tusamitamab SonditecanPhase 1Antibody–drug conjugateCEACAM5not yet gradedNo reviewed efficacy summary in this indication
NaporafenibDiscontinuedSmall moleculePan-RAFWeak signal
NCT02607813: 142 patients were treated across the naporafenib dose-escalation (n = 87), naporafenib plus spartalizumab dose-escalation (n = 12) and dose-expansion (n = 43) arms. The maximum tolerated and recommended dose for single-agent naporafenib was 600 mg twice daily. Five patients in the naporafenib escalation arm had 7 dose-limiting toxicities, including decreased platelet count at 1200 mg once daily, neuralgia, maculopapular rash and pruritus at 600 mg twice daily, and increased blood bilirubin, hyponatremia and peripheral sensory neuropathy at 800 mg twice daily.

Large race: only the 132 furthest-along competitors are listed; 480 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(208 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Atezolizumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (26)
November 2026 (7)
Phase 1Newly Diagnosed H3-mutated GliomaActive not recruiting
Est. primary completion 2026-11 · NCT04808245 · CT.gov ↗
What to watch
Phase 2Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8 …Active not recruiting
Est. primary completion 2026-11 · NCT05168618 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-11 · NCT04958811 · CT.gov ↗
What to watch
Phase 1Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid NeoplasmActive not recruiting
Est. primary completion 2026-11-21 · NCT02862275 · CT.gov ↗
What to watch
Phase 1Recurrent GlioblastomaRecruiting
Est. primary completion 2026-11-27 · NCT07538128 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-11-30 · NCT04302025 · CT.gov ↗
What to watch
Phase 3CancerActive not recruiting
Est. primary completion 2026-11-30 · NCT03148418 · CT.gov ↗
What to watch
December 2026 (19)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT04691817 · CT.gov ↗
What to watch
Phase 1/2Bladder CancerRecruiting
Est. primary completion 2026-12 · NCT05000294 · CT.gov ↗
What to watch
Phase 1/2Bladder CancerActive not recruiting
Est. primary completion 2026-12 · NCT02989584 · CT.gov ↗
What to watch
Phase 2HER2-positive Breast CancerActive not recruiting
Est. primary completion 2026-12 · NCT03125928 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT03786692 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT03915678 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2026-12-01 · NCT07192185 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12-01 · NCT05825625 · CT.gov ↗
What to watch
Phase 1/2Relapsed or Refractory Hodgkin's LymphomaActive not recruiting
Est. primary completion 2026-12-15 · NCT05300282 · CT.gov ↗
What to watch
Phase 2Triple Negative Breast CancerRecruiting
Est. primary completion 2026-12-15 · NCT06690840 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-15 · NCT06771518 · CT.gov ↗
What to watch
Phase 3Invasive Breast CancerActive not recruiting
Est. primary completion 2026-12-15 · NCT03595592 · CT.gov ↗
What to watch
Phase 2Oropharynx Cancer, Stage IRecruiting
Est. primary completion 2026-12-16 · NCT06254911 · CT.gov ↗
What to watch
Phase 1Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C MutationActive not recruiting
Est. primary completion 2026-12-17 · NCT04185883 · CT.gov ↗
What to watch
Phase 2Sarcoma,Soft TissueActive not recruiting
Est. primary completion 2026-12-30 · NCT03474094 · CT.gov ↗
What to watch
Phase 2Breast Cancer, Triple Negative Breast Cancer, Residual Cancer, Circulating Tumor DNARecruiting
Est. primary completion 2026-12-30 · NCT04434040 · CT.gov ↗
What to watch
Phase 1Hepatocellular CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT05488522 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT05340309 · CT.gov ↗
What to watch
Phase 2Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 …Active not recruiting
Est. primary completion 2026-12-31 · NCT03784326 · CT.gov ↗
What to watch
2027 (92)
January 2027 (8)
Phase 1Small Cell Lung CancerRecruiting
Est. primary completion 2027-01 · NCT06807632 · CT.gov ↗
What to watch
Phase 1/2Solid Tumor, RhabdomyosarcomaActive not recruiting
Est. primary completion 2027-01 · NCT04796012 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-01-01 · NCT04467723 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-01-01 · NCT06731270 · CT.gov ↗
What to watch
Phase 2Hepato Cellular Carcinoma (HCC)Recruiting
Est. primary completion 2027-01-01 · NCT07276100 · CT.gov ↗
What to watch
Phase 1Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-01-27 · NCT04560972 · CT.gov ↗
What to watch
Phase 1Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-01-31 · NCT05096715 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-01-31 · NCT06066138 · CT.gov ↗
What to watch
February 2027 (4)
Phase 2Bladder CancerActive not recruiting
Est. primary completion 2027-02 · NCT04186013 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-02 · NCT05798663 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2027-02-15 · NCT05377034 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic Leukemia, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia …Active not recruiting
Est. primary completion 2027-02-28 · NCT02846623 · CT.gov ↗
What to watch
March 2027 (7)
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-03 · NCT07246668 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-03 · NCT05516628 · CT.gov ↗
What to watch
Phase 2/3Colorectal CancerActive not recruiting
Est. primary completion 2027-03 · NCT05141721 · CT.gov ↗
What to watch
Phase 1Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin NeoplasmActive not recruiting
Est. primary completion 2027-03-31 · NCT04387084 · CT.gov ↗
What to watch
Phase 1Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-03-31 · NCT06077500 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2027-03-31 · NCT06830694 · CT.gov ↗
What to watch
Phase 3Breast CancerActive not recruiting
Est. primary completion 2027-03-31 · NCT04873362 · CT.gov ↗
What to watch
April 2027 (5)
Phase 2Colorectal CancerActive not recruiting
Est. primary completion 2027-04 · NCT05118724 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorRecruiting
Est. primary completion 2027-04-06 · NCT05434234 · CT.gov ↗
What to watch
Early phase / not applicableHepatocellular CarcinomaRecruiting
Est. primary completion 2027-04-25 · NCT06595108 · CT.gov ↗
What to watch
Phase 2Prostate Adenocarcinoma, Prostate Cancer, Localized Prostate CancerRecruiting
Est. primary completion 2027-04-30 · NCT03821246 · CT.gov ↗
What to watch
Phase 4Hepatocellular CarcinomaEnrolling by invitation
Est. primary completion 2027-04-30 · NCT05185505 · CT.gov ↗
What to watch
May 2027 (9)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-05 · NCT03896074 · CT.gov ↗
What to watch
Phase 2Advanced Solid TumorRecruiting
Est. primary completion 2027-05 · NCT03767075 · CT.gov ↗
What to watch
Phase 2Advanced Alveolar Soft Part Sarcoma, Advanced Soft Tissue Sarcoma, Metastatic Alveolar Soft Part Sarcoma …Recruiting
Est. primary completion 2027-05-01 · NCT05333458 · CT.gov ↗
What to watch
Phase 1Cancer-NeoplasmsActive not recruiting
Est. primary completion 2027-05-12 · NCT06537310 · CT.gov ↗
What to watch
Phase 1/2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-05-25 · NCT05440708 · CT.gov ↗
What to watch
Phase 1Small Cell Lung CancerRecruiting
Est. primary completion 2027-05-30 · NCT06179069 · CT.gov ↗
What to watch
Phase 2Gastric Cancer, Gastroesophageal Junction AdenocarcinomaActive not recruiting
Est. primary completion 2027-05-31 · NCT03421288 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2027-05-31 · NCT04721132 · CT.gov ↗
What to watch
Phase 2Triple Negative Breast CancerActive not recruiting
Est. primary completion 2027-05-31 · NCT05498896 · CT.gov ↗
What to watch
June 2027 (11)
Phase 1Osteosarcoma, Pulmonary Recurrence of OsteosarcomaRecruiting
Est. primary completion 2027-06 · NCT06492954 · CT.gov ↗
What to watch
Phase 2Prostate CancerRecruiting
Est. primary completion 2027-06-01 · NCT04812366 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-06-01 · NCT04310020 · CT.gov ↗
What to watch
Phase 3Colorectal CancerActive not recruiting
Est. primary completion 2027-06-01 · NCT02997228 · CT.gov ↗
What to watch
Phase 1Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma …Active not recruiting
Est. primary completion 2027-06-30 · NCT03321643 · CT.gov ↗
What to watch
Phase 1/2Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung CancerRecruiting
Est. primary completion 2027-06-30 · NCT06110572 · CT.gov ↗
What to watch
Phase 1/2Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related ChangesActive not recruiting
Est. primary completion 2027-06-30 · NCT02935361 · CT.gov ↗
What to watch
Phase 2Neoplasm MetastasisActive not recruiting
Est. primary completion 2027-06-30 · NCT00781612 · CT.gov ↗
What to watch
Phase 2Bladder CancerActive not recruiting
Est. primary completion 2027-06-30 · NCT03237780 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-06-30 · NCT03178552 · CT.gov ↗
What to watch
Phase 3NeoplasmsActive not recruiting
Est. primary completion 2027-06-30 · NCT05112965 · CT.gov ↗
What to watch
July 2027 (14)
Phase 1Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-07 · NCT05595460 · CT.gov ↗
What to watch
Phase 3Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-07 · NCT04803994 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2027-07-01 · NCT04696575 · CT.gov ↗
What to watch
Phase 2CancerActive not recruiting
Est. primary completion 2027-07-01 · NCT06754501 · CT.gov ↗
What to watch
Phase 2Metastatic Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8Active not recruiting
Est. primary completion 2027-07-01 · NCT05411081 · CT.gov ↗
What to watch
Phase 1/2Small Cell Lung CancerRecruiting
Est. primary completion 2027-07-20 · NCT06362252 · CT.gov ↗
What to watch
Phase 1PIK3CA-Mutated CancersActive not recruiting
Est. primary completion 2027-07-21 · NCT06496568 · CT.gov ↗
What to watch
Phase 1Advanced Solid Tumor, LymphomaActive not recruiting
Est. primary completion 2027-07-30 · NCT05878691 · CT.gov ↗
What to watch
Phase 1/2Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic …Active not recruiting
Est. primary completion 2027-07-30 · NCT07280377 · CT.gov ↗
What to watch
Phase 1/2Advanced Liver CancersActive not recruiting
Est. primary completion 2027-07-30 · NCT04524871 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2027-07-30 · NCT06096779 · CT.gov ↗
What to watch
Phase 3Mesotheliomas PleuralRecruiting
Est. primary completion 2027-07-30 · NCT04996017 · CT.gov ↗
What to watch
Phase 2Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8 …Active not recruiting
Est. primary completion 2027-07-31 · NCT03181100 · CT.gov ↗
What to watch
Phase 2Cancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck CancerActive not recruiting
Est. primary completion 2027-07-31 · NCT03708224 · CT.gov ↗
What to watch
August 2027 (5)
Phase 1Glioblastoma MultiformeRecruiting
Est. primary completion 2027-08 · NCT05423210 · CT.gov ↗
What to watch
Phase 1/2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-08 · NCT06695026 · CT.gov ↗
What to watch
Phase 2Peritoneal Malignant MesotheliomaRecruiting
Est. primary completion 2027-08-01 · NCT05001880 · CT.gov ↗
What to watch
Phase 4Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-08-01 · NCT07059494 · CT.gov ↗
What to watch
Phase 3Venous ThrombosisActive not recruiting
Est. primary completion 2027-08-31 · NCT04649489 · CT.gov ↗
What to watch
September 2027 (6)
Phase 2Cancer, Tumors, Neoplasm, NeoplasiaRecruiting
Est. primary completion 2027-09 · NCT02925234 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-09-01 · NCT07774247 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-09-01 · NCT04253964 · CT.gov ↗
What to watch
Phase 1Locally Advanced Skin Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma, Unresectable Skin Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2027-09-10 · NCT05085496 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-09-30 · NCT06444815 · CT.gov ↗
What to watch
Phase 2Appendix Adenocarcinoma, Human Papillomavirus-Related Anal Squamous Cell Carcinoma …Active not recruiting
Est. primary completion 2027-09-30 · NCT03074513 · CT.gov ↗
What to watch
October 2027 (6)
Phase 1/2Malignant Pleural MesotheliomaRecruiting
Est. primary completion 2027-10 · NCT05765084 · CT.gov ↗
What to watch
Phase 2Bladder CancerRecruiting
Est. primary completion 2027-10 · NCT05312671 · CT.gov ↗
What to watch
Phase 2Unresectable Gastrointestinal Stromal Tumor (GIST), Locally Advanced Gastrointestinal Stromal Tumor (GIST) …Active not recruiting
Est. primary completion 2027-10 · NCT05152472 · CT.gov ↗
What to watch
Phase 2Breast Cancer, Lung Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Gynecologic Cancer, Sarcoma, Unknown Primary Tumors …Active not recruiting
Est. primary completion 2027-10 · NCT04273061 · CT.gov ↗
What to watch
Phase 1Solid TumorRecruiting
Est. primary completion 2027-10-31 · NCT05907980 · CT.gov ↗
What to watch
Phase 2Metastatic Alveolar Soft Part Sarcoma, Unresectable Alveolar Soft Part SarcomaActive not recruiting
Est. primary completion 2027-10-31 · NCT03141684 · CT.gov ↗
What to watch
November 2027 (3)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-11 · NCT06332755 · CT.gov ↗
What to watch
Phase 2Small Cell Carcinoma of the Bladder, Small Cell Carcinoma of the Urinary Tract, Squamous Cell Carcinoma of the Bladder …Recruiting
Est. primary completion 2027-11-01 · NCT06161532 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-11-10 · NCT07239245 · CT.gov ↗
What to watch
December 2027 (14)
Phase 1/2Small Cell Lung CancerRecruiting
Est. primary completion 2027-12 · NCT05652686 · CT.gov ↗
What to watch
Phase 1/2Small Cell Lung CancerRecruiting
Est. primary completion 2027-12 · NCT05703971 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2027-12 · NCT07654400 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-12-01 · NCT05733598 · CT.gov ↗
What to watch
Phase 2/3Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma …Active not recruiting
Est. primary completion 2027-12-15 · NCT05063552 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-30 · NCT04919382 · CT.gov ↗
What to watch
Phase 1Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT06478693 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT04449874 · CT.gov ↗
What to watch
Phase 1/2Recurrent Glioblastoma, Recurrent GliosarcomaActive not recruiting
Est. primary completion 2027-12-31 · NCT05039281 · CT.gov ↗
What to watch
Phase 2Rare TumourNot yet recruiting
Est. primary completion 2027-12-31 · NCT06692491 · CT.gov ↗
What to watch
Phase 2Locally Advanced Osteosarcoma, Metastatic Osteosarcoma, Recurrent Osteosarcoma, Refractory Osteosarcoma, Unresectable OsteosarcomaRecruiting
Est. primary completion 2027-12-31 · NCT05019703 · CT.gov ↗
What to watch
Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2027-12-31 · NCT02693535 · CT.gov ↗
What to watch
Phase 2Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory CarcinomaActive not recruiting
Est. primary completion 2027-12-31 · NCT03202316 · CT.gov ↗
What to watch
Phase 2Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma …Recruiting
Est. primary completion 2027-12-31 · NCT04981509 · CT.gov ↗
What to watch
2028 (44)
January 2028 (9)
Phase 1/2Solid CancerActive not recruiting
Est. primary completion 2028-01-01 · NCT06771622 · CT.gov ↗
What to watch
Phase 2Recurrent GlioblastomaRecruiting
Est. primary completion 2028-01-01 · NCT06069726 · CT.gov ↗
What to watch
Phase 2Solid Tumor, AdultActive not recruiting
Est. primary completion 2028-01-01 · NCT06003621 · CT.gov ↗
What to watch
Phase 2Soft Tissue SarcomaRecruiting
Est. primary completion 2028-01-01 · NCT07049848 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic Leukemia, Richter's TransformationRecruiting
Est. primary completion 2028-01-15 · NCT06043674 · CT.gov ↗
What to watch
Phase 1/2Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-01-28 · NCT04471727 · CT.gov ↗
What to watch
Phase 1/2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-01-30 · NCT06294548 · CT.gov ↗
What to watch
Phase 2Large Cell Neuroendocrine Carcinoma of the LungActive not recruiting
Est. primary completion 2028-01-31 · NCT05470595 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-01-31 · NCT02525757 · CT.gov ↗
What to watch
February 2028 (4)
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2028-02 · NCT04727307 · CT.gov ↗
What to watch
Phase 1Endometrial Cancer, Metastasis, Endometrioid Endometrial Cancer, Carcinosarcoma, Serous Adenocarcinoma of Endometrium (Diagnosis) …Recruiting
Est. primary completion 2028-02-21 · NCT05542407 · CT.gov ↗
What to watch
Phase 1/2Advanced Cholangiocarcinoma, FGFR2 FusionRecruiting
Est. primary completion 2028-02-22 · NCT06439485 · CT.gov ↗
What to watch
Phase 2Ovarian CancerActive not recruiting
Est. primary completion 2028-02-28 · NCT04931342 · CT.gov ↗
What to watch
March 2028 (4)
Phase 1Locally Advanced Solid Tumors, Recurrent Solid Tumors, Metastatic Solid TumorsActive not recruiting
Est. primary completion 2028-03-01 · NCT06031441 · CT.gov ↗
What to watch
Phase 1/2Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-03-07 · NCT05142696 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-03-27 · NCT05528952 · CT.gov ↗
What to watch
Phase 2Glioblastoma, Recurrence TumorRecruiting
Est. primary completion 2028-03-30 · NCT07263438 · CT.gov ↗
What to watch
April 2028 (1)
Phase 3Colorectal CancerRecruiting
Est. primary completion 2028-04-01 · NCT06733038 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2MelanomaActive not recruiting
Est. primary completion 2028-06-30 · NCT03175432 · CT.gov ↗
What to watch
July 2028 (5)
Phase 1Colorectal CancerRecruiting
Est. primary completion 2028-07 · NCT06012734 · CT.gov ↗
What to watch
Phase 4Oncology, Infusion ReactionRecruiting
Est. primary completion 2028-07 · NCT06031233 · CT.gov ↗
What to watch
Phase 3Advanced CancerNot yet recruiting
Est. primary completion 2028-07-03 · NCT07929051 · CT.gov ↗
What to watch
Phase 3CancerActive not recruiting
Est. primary completion 2028-07-05 · NCT03768063 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-07-31 · NCT05581004 · CT.gov ↗
What to watch
August 2028 (2)
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2028-08-30 · NCT06663098 · CT.gov ↗
What to watch
Early phase / not applicableHepatocellular CarcinomaNot yet recruiting
Est. primary completion 2028-08-31 · NCT07543510 · CT.gov ↗
What to watch
September 2028 (3)
Phase 3Small Cell Lung CancerRecruiting
Est. primary completion 2028-09-09 · NCT07472517 · CT.gov ↗
What to watch
Phase 1Advanced Solid MalignanciesActive not recruiting
Est. primary completion 2028-09-15 · NCT06760481 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-09-30 · NCT06133062 · CT.gov ↗
What to watch
October 2028 (4)
Phase 2Cervical Cancer, Cervical Cancer Recurrent, Cervical Cancer MetastaticActive not recruiting
Est. primary completion 2028-10 · NCT03614949 · CT.gov ↗
What to watch
Phase 2/3Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma …Recruiting
Est. primary completion 2028-10-01 · NCT05058651 · CT.gov ↗
What to watch
Phase 1NeoplasmsRecruiting
Est. primary completion 2028-10-16 · NCT06551142 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-10-27 · NCT06789757 · CT.gov ↗
What to watch
November 2028 (3)
Phase 1/2Small Cell Lung CancerRecruiting
Est. primary completion 2028-11 · NCT07407933 · CT.gov ↗
What to watch
Phase 2Squamous Cell Carcinoma, Oral Cavity Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2028-11-01 · NCT05681039 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-11-30 · NCT05334329 · CT.gov ↗
What to watch
December 2028 (8)
Phase 1Treatment-Refractory Solid TumorsNot yet recruiting
Est. primary completion 2028-12 · NCT07170592 · CT.gov ↗
What to watch
Phase 1Treatment-Refractory Solid TumorsRecruiting
Est. primary completion 2028-12 · NCT07190833 · CT.gov ↗
What to watch
Phase 3Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2028-12 · NCT06680258 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-12-05 · NCT07317414 · CT.gov ↗
What to watch
Phase 1/2Metastatic MalignancyActive not recruiting
Est. primary completion 2028-12-31 · NCT05394337 · CT.gov ↗
What to watch
Phase 1/2Colorectal CancerRecruiting
Est. primary completion 2028-12-31 · NCT05944237 · CT.gov ↗
What to watch
Phase 2Rectal CancerActive not recruiting
Est. primary completion 2028-12-31 · NCT04017455 · CT.gov ↗
What to watch
Early phase / not applicableHepatocellular CarcinomaNot yet recruiting
Est. primary completion 2028-12-31 · NCT07281664 · CT.gov ↗
What to watch
2029 (17)
February 2029 (2)
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2029-02-01 · NCT07339059 · CT.gov ↗
What to watch
Phase 3Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2029-02-01 · NCT04712643 · CT.gov ↗
What to watch
March 2029 (3)
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2029-03-30 · NCT06339424 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2029-03-31 · NCT07010497 · CT.gov ↗
What to watch
Phase 2HCCRecruiting
Est. primary completion 2029-03-31 · NCT06823375 · CT.gov ↗
What to watch
April 2029 (3)
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2029-04 · NCT07155174 · CT.gov ↗
What to watch
Phase 2Cancer, Tumors, Neoplasms, NeoplasiaRecruiting
Est. primary completion 2029-04-30 · NCT04341181 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-04-30 · NCT06632327 · CT.gov ↗
What to watch
May 2029 (1)
Phase 1/2Inoperable, Locally Advanced or Metastatic, ER-positive Breast CancerRecruiting
Est. primary completion 2029-05-30 · NCT04802759 · CT.gov ↗
What to watch
June 2029 (2)
Phase 3Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2029-06-01 · NCT07461675 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2029-06-30 · NCT06605664 · CT.gov ↗
What to watch
July 2029 (1)
Phase 1/2Small Cell Lung CancerRecruiting
Est. primary completion 2029-07-25 · NCT06287775 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-08-31 · NCT03228667 · CT.gov ↗
What to watch
September 2029 (1)
Phase 1Small Cell Lung CancerRecruiting
Est. primary completion 2029-09-30 · NCT07545954 · CT.gov ↗
What to watch
October 2029 (3)
Phase 2/3Colorectal CancerRecruiting
Est. primary completion 2029-10 · NCT05770102 · CT.gov ↗
What to watch
Phase 2/3Haematological Malignancy, Solid TumourRecruiting
Est. primary completion 2029-10 · NCT05722886 · CT.gov ↗
What to watch
Phase 1/2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2029-10-01 · NCT07835737 · CT.gov ↗
What to watch
2030 (13)
January 2030 (3)
Phase 1Small Cell Lung CancerRecruiting
Est. primary completion 2030-01 · NCT07113691 · CT.gov ↗
What to watch
Phase 3Small Cell Lung CancerRecruiting
Est. primary completion 2030-01 · NCT07625644 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2030-01-01 · NCT06254248 · CT.gov ↗
What to watch
March 2030 (2)
Phase 2Early-stage Breast CancerRecruiting
Est. primary completion 2030-03 · NCT05332561 · CT.gov ↗
What to watch
Phase 1/2Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma, Malignant Solid Neoplasm …Active not recruiting
Est. primary completion 2030-03-31 · NCT05286801 · CT.gov ↗
What to watch
April 2030 (1)
Phase 1/2Small Cell Lung CancerRecruiting
Est. primary completion 2030-04-26 · NCT07707895 · CT.gov ↗
What to watch
May 2030 (2)
Phase 1Small Cell Lung CancerActive not recruiting
Est. primary completion 2030-05-30 · NCT05361395 · CT.gov ↗
What to watch
Phase 3Colorectal CancerEnrolling by invitation
Est. primary completion 2030-05-31 · NCT07620574 · CT.gov ↗
What to watch
August 2030 (2)
Phase 1Colorectal CancerRecruiting
Est. primary completion 2030-08-31 · NCT04929223 · CT.gov ↗
What to watch
Phase 1/2Hepatocellular CarcinomaRecruiting
Est. primary completion 2030-08-31 · NCT03942328 · CT.gov ↗
What to watch
September 2030 (1)
Phase 1/2Metastatic Breast CancerRecruiting
Est. primary completion 2030-09-30 · NCT03424005 · CT.gov ↗
What to watch
November 2030 (2)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-11-01 · NCT07322341 · CT.gov ↗
What to watch
Phase 1/2Small Cell Lung CancerRecruiting
Est. primary completion 2030-11-29 · NCT07227597 · CT.gov ↗
What to watch
2031 (8)
January 2031 (1)
Phase 2Adenocarcinoma, Pancreatic DuctalActive not recruiting
Est. primary completion 2031-01-01 · NCT05968326 · CT.gov ↗
What to watch
February 2031 (1)
Phase 3Small Cell Lung CancerNot yet recruiting
Est. primary completion 2031-02-24 · NCT07947121 · CT.gov ↗
What to watch
June 2031 (2)
Phase 1/2Hepatocellular CarcinomaRecruiting
Est. primary completion 2031-06 · NCT06725121 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2031-06 · NCT07018947 · CT.gov ↗
What to watch
August 2031 (2)
Phase 2Small Cell Lung CancerNot yet recruiting
Est. primary completion 2031-08 · NCT07895056 · CT.gov ↗
What to watch
Phase 2Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, PARP Inhibitor, Hedgehog InhibitorRecruiting
Est. primary completion 2031-08-30 · NCT05538091 · CT.gov ↗
What to watch
November 2031 (1)
Phase 2Advanced Cancer, Solid Tumor, Haematological MalignancyRecruiting
Est. primary completion 2031-11-25 · NCT05159245 · CT.gov ↗
What to watch
December 2031 (1)
Phase 2Small Cell Lung CancerNot yet recruiting
Est. primary completion 2031-12 · NCT07895043 · CT.gov ↗
What to watch
2032 (3)
June 2032 (1)
Phase 1/2Hepatocellular CarcinomaRecruiting
Est. primary completion 2032-06 · NCT05468359 · CT.gov ↗
What to watch
September 2032 (2)
Phase 2Solid TumorsActive not recruiting
Est. primary completion 2032-09-25 · NCT04589845 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2032-09-30 · NCT07388524 · CT.gov ↗
What to watch
2033 (1)
March 2033 (1)
Phase 3CancerRecruiting
Est. primary completion 2033-03-01 · NCT05862285 · CT.gov ↗
What to watch
2035 (1)
May 2035 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2035-05-02 · NCT07153445 · CT.gov ↗
What to watch
2040 (3)
February 2040 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2040-02-28 · NCT07770100 · CT.gov ↗
What to watch
March 2040 (1)
Phase 2Cancer MetastaticRecruiting
Est. primary completion 2040-03-30 · NCT04817956 · CT.gov ↗
What to watch
July 2040 (1)
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2040-07-01 · NCT05620771 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

9 October 2026ApprovalFDA approves Tecentriq for adjuvant stage III dMMR colon cancer
US, FDA · Roche · Source ↗
7 October 2025FDA action datePDUFA date set for October 7, 2025
US, FDA · Source ↗
2 October 2025ApprovalFDA approves Zepzelca plus atezolizumab as first-line maintenance for ES-SCLC
US, FDA · Source ↗
10 June 2025Filing acceptedFDA accepts sNDA for Zepzelca plus atezolizumab
US, FDA · Source ↗
10 June 2025Priority reviewFDA grants Priority Review
US, FDA · Source ↗